Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancerValentina Guarneri, PierFranco Conte, Federica Miglietta et al.|IRIS UNIMORE (University of Modena and Reggio Emilia)|2020Cited by 0